Literature DB >> 16417239

Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides -- cutaneous T cell lymphoma.

Henry K Wong1, Adam J Wilson, Heather M Gibson, Mikehl S Hafner, Carrie J Hedgcock, Carole L Berger, Richard L Edelson, Henry W Lim.   

Abstract

Mycosis fungoides (MF) is a low-grade lymphoma of cluster of differentiation (CD)4+, CD45RO+, cutaneous leukocyte antigen (CLA)+ T cells that homes to the skin. To understand the functional abnormalities in this disease, we study the regulation of cytotoxic T-lymphocyte antigen (CTLA)-4 in peripheral blood mononuclear cells (PBMCs) from patients with MF. CTLA-4 is a costimulatory molecule for T cells that functions in immunoregulation. Unlike the expression of CD28, which is expressed constitutively on T cells, CTLA-4 expression is highly regulated. In the analysis of PBMCs in MF, we found that CTLA-4 is stimulated by phorbol myristate acetate/A23187 to a greater level when compared to normals. This defect was seen in the dominant clones of T cells. The increased CTLA-4 expression was significant between normal and MF, with a correlation between higher expression of CTLA-4 and a higher grade of MF. In a patient whose disease progressed, the CTLA-4 level increased. The abnormal level of CTLA-4 was confirmed at both the transcription and translation levels. Although MF is associated with a Th2 bias, Th1 cytokines IL-2 and IFN-gamma enhanced CTLA-4 expression, while IL-4 did not. These findings reveal an abnormal regulation of CTLA-4 expression in MF and show that PBMCs from patients with MF have properties that are divergent from those of normal T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417239     DOI: 10.1038/sj.jid.5700029

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  28 in total

1.  Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter.

Authors:  Heather M Gibson; Carrie J Hedgcock; Barbara M Aufiero; Adam J Wilson; Mikehl S Hafner; George C Tsokos; Henry K Wong
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

Review 2.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

Review 3.  Sézary Syndrome: Clinical and Biological Aspects.

Authors:  Rebecca Kohnken; Stephanie Fabbro; Justin Hastings; Pierluigi Porcu; Anjali Mishra
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

4.  Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface.

Authors:  Jin-Sung Chung; Lisa H Shiue; Madeleine Duvic; Amit Pandya; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2011-01-20       Impact factor: 22.113

Review 5.  Mycosis fungoides and sezary syndrome: an update.

Authors:  Ellen J Kim; Julie Lin; Jacqueline M Junkins-Hopkins; Carmela C Vittorio; Alain H Rook
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

6.  Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.

Authors:  Elisabetta Capriotti; Eric C Vonderheid; Christopher J Thoburn; Mariusz A Wasik; David W Bahler; Allan D Hess
Journal:  Leuk Lymphoma       Date:  2008-06

7.  CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Authors:  Andreas Herrmann; Saul J Priceman; Piotr Swiderski; Maciej Kujawski; Hong Xin; Gregory A Cherryholmes; Wang Zhang; Chunyan Zhang; Christoph Lahtz; Claudia Kowolik; Steve J Forman; Marcin Kortylewski; Hua Yu
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

8.  Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides.

Authors:  Benjamin F Chong; Adam J Wilson; Heather M Gibson; Mikehl S Hafner; Yu Luo; Carrie J Hedgcock; Henry K Wong
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

Review 9.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08

10.  Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome.

Authors:  Heather M Gibson; Anjali Mishra; Derek V Chan; Timothy S Hake; Pierluigi Porcu; Henry K Wong
Journal:  J Invest Dermatol       Date:  2012-09-06       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.